论文部分内容阅读
用低剂量ＩＬ－２，同时加入人ＲＢＣ诱导制备同种异体ＬＡＫ细胞，可见ＬＡＫ细胞的增殖明显和杀伤活性显著提高。用自制的复方白细胞介素２及ＬＡＫ细胞组成ＬＡＫ细胞联合复方白细胞介素２（ＬＡＫ／ＩＬ－２Ｃｏ．）过继免疫疗法和联合放疗、化疗的综合疗法，共治疗中、晚期恶性肿瘤１３８例，疗效结果判定，单纯免疫疗法治疗组，无ＣＲ，ＰＲ３０．３％，综合疗法治疗组ＣＲ＋ＰＲ为５８％，且副反应均较轻，本项应用研究结果是安全有效的，能作为抗肿瘤优选的治疗方案
With the use of low dose of IL-2 and simultaneous addition of human RBC to induce allogeneic LAK cells, the proliferation and killing activity of LAK cells were significantly increased. Using self-made compound interleukin 2 and LAK cells, LAK cells combined with compound interleukin 2 (LAK/IL-2Co.) adoptive immunotherapy and combined radiotherapy and chemotherapy combined therapy to treat 138 cases of middle and late stage malignant tumors. The efficacy results showed that only immunotherapy group, no CR, PR30.3%, comprehensive treatment group CR+PR was 58%, and the side effects were mild, the results of this application study is safe and effective, can be used as anti-tumor optimal Treatment programs